22nd January 2019
Glioma is an often invasive cancer displaying a heterogeneous cell population derived from transformed glial cells. To date there are limited trustworthy biomarkers for the detection and risk stratification of glioma. The objective of the present research was to select DNA aptamers to facilitate early diagnosis and effective therapy of glioma.
Aptamers were developed to human glioblastoma cell line T98G using convention cell SELEX techniques, using a normal glial cell line (SVGp12) as a counter target. Binding properties of the developed aptamers were assessed by flow cytometry. The aptamer specificity was assessed by incubating the aptamers with seven other cancer as well as healthy astrocyte cell lines, to which the selected aptamers did not bind. Aptamer stability and binding was tested in human cerebral spinal fluid (CFS) and fetal bovine serum (FBS). Aptamers were stable over the two hour test period and binding remained efficient in both FBS and CFS, showing potential for future in vivo studies as well as clinical and therapeutic applications.
Wu, Q., Wang, Y., Wang, H., Wu, L., Zhang, H., Song, Y., Zhu, Z., Kang, D. and Yang, C. (2018). DNA aptamers from whole-cell SELEX as new diagnostic agents against glioblastoma multiforme cells. The Analyst, 143(10), pp.2267-2275..
Aptamer Group has also successfully selected cell biomarkers to whole cells in tumour models, if you are interested in exploring biomarker development further contact us using the form below.